Meeting
2019 ASCO Annual Meeting
A randomized, multicenter clinical trial to determine the efficacy and safety of pegfilgrastim (GEMA BIOTECH) compared to pegfilgrastim (Roche) for prevention of chemotherapy induced neutropenia in patients with breast cancer.
Authors
Martin Eduardo Richardet
Sanatorio Acongacua, Cordoba, Argentina
Martin Eduardo Richardet , Ruben Dario Kowalyszyn , Mirta Susana Varela , Eduardo Ortiz , Cristian Micheri , Juan Jose Zarba , Susana Kahl , Ezequiel Klimovsky , Andrea Alicia Federico , Luis Enrique Fein , Jorge Horacio Cassini , Gustavo Cortese , Florencia Visintini Jaime , Lucas Cordeiro , Nestor Ruben Lago
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics and Tumor Biology (Nonimmuno)
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Other Developmental Therapeutics
Clinical Trial Registration Number
NCT03404752
Citation
J Clin Oncol 37, 2019 (suppl; abstr 3113)
DOI
10.1200/JCO.2019.37.15_suppl.3113
Abstract #
3113
Poster Bd #
105
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim for the prevention of severe neutropenia, in patients with breast cancer receiving myelosuppressive chemotherapy.
First Author: Andriy Krendyukov
Poster
2021 ASCO Annual Meeting
Chemotherapy induced profound neutropenia (PN) in patients (pt) with breast cancer (BC) after chemotherapy and plinabulin (Plin) plus pegfilgrastim (Peg) combination versus (vs) peg alone: Final phase 3 results from protective-2 (BPI-2358-106).
First Author: Yuankai Shi
Poster
2022 ASCO Annual Meeting
Efficacy of olanzapine, netupitant, and palonosetron in controlling nausea and vomiting associated with highly emetogenic chemotherapy in patients with breast cancer (OLNEPA).
First Author: Camilla Vieira de Reboucas
Poster
2021 ASCO Quality Care Symposium
Association of primary prophylactic (PP) granulocyte-colony stimulating factor (G-CSF) use with chemotherapy dose modifications and relative dose intensity (RDI) among breast cancer patients receiving high-risk regimens for febrile neutropenia (FN).
First Author: Jaime Shaw